3X4 Genetics

Biomica | October 13, 2020

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Regeneron | July 07, 2020

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

MEDICAL

Berkery, Noyes & Co. | October 08, 2021

Entopsis, Inc., the developer of an unbiased approach to diagnostics using bio-molecular signatures with a focus on oncology, announced that it has engaged Berkery Noyes & Co. as its financial advisor to assist the company in pursuing strategic alternatives for their OpsisDxTM platform. OpsisDxTM is a urine-based technology platform that shifts the focus away from conventional RNA and DNA approaches, offering a highly sensitive and specific diagnostic test for the detection of...

Repurpose.AI | July 01, 2020

Repurpose.AI, an AI drug discovery company, today announced the launch of an Open Innovation Partnership with LEO Pharma A/S, a global leader in medical dermatology, to discover and validate drugs to treat inflammatory and dermatology indications.The research collaboration will leverage Repurpose.AI's ActivPred AI Drug Discovery Platform, an unbiased drug, target and disease agnostic digital chemistry engine, to discover drug candidates for inflammatory skin diseases. Previously, the c...